Nearly 80% of cystic fibrosis heterozygotes and 64% of couples at risk may be detected through a unique screening of four mutations by ASO reverse dot blot.
A technique allowing the simultaneous screening of the four main CF mutations in the French population (delta F508, delta I507, G542X, S549N) has been developed by means of allele sequence-specific oligonucleotide (ASO) reverse dot blot. Using a strategy proposed by R. K. Saïki et al. (1989, Proc. Natl. Acad. Sci. USA 86: 6230-6234) for HLA-DQA, the seven ASOs for normal and mutant CF alleles were given a homopolymer T tail with terminal deoxyribonucleotidyltransferase and then immobilized on a nylon membrane. T-tail homopolymers were preferentially bound to the nylon, leaving the specific ASO sequences free to hybridize with amplified and radiolabeled exons 10 and 11 of a patient. These exons were simultaneously coamplified by a multiplex PCR and radiolabeled by random priming. ASO reverse dot blot currently appears to be the most efficient, rapid, and economic means of screening the population for CF mutations. This screening can detect nearly 80% of carriers and 64% of couples at risk and could prevent the birth of CF-affected infants in these families.
Serre
J L
JL
Laboratoire de Génétique Epidémiologique, INSERM U.155, Paris, France.
Taillandier
A
A
Mornet
E
E
Simon-Bouy
B
B
Boué
J
J
Boué
A
A
D000483:Alleles; D001483:Base Sequence; D003550:Cystic Fibrosis / Q000175:diagnosis / Q000235:genetics*; D004247:DNA; D003854:Deoxyribonucleotides / Q000235:genetics*; D005602:France; D006580:Genetic Carrier Screening; D005820:Genetic Testing; D006801:Humans; D015151:Immunoblotting / Q000379:methods; D008969:Molecular Sequence Data; D009154:Mutation; D016133:Polymerase Chain Reaction; D012306:Risk
D003854:Deoxyribonucleotides; D004247:DNA